Download Champions' latest AACR 2024 Poster

A Novel 3D Co-Culture Platform for Patient-Specific Immune-Oncology Treatment

In the past decade, the success of checkpoint inhibitor therapy has led to an increase in test agents targeting the tumor immune microenvironment (TIME). However, it has also highlighted the patient-specific nature of responses emphasizing the need for patient stratification in preclinical testing. Current in vitro immune models often rely on immortalized cell lines with PBMCs, which don't always translate to clinical outcomes. Champions Oncology addresses this gap by combining patient-derived xenografts and biopsies with immune cells like NK cells, PBMCs, and TILs, creating deeply translational models that provide predictive insights into efficacy and mechanisms.

• Champions’ TumorGraft3D platform offers a variety of highly characterized models of human cancer across various indications.
• The TumorGraft3D co-culture assay can be performed with a variety of immune cell sources including PBMCs, NK cells, and autologous TILs.
• Champions’ novel co-culture platform allows screening of immune targeting agents to determine impact on tumor cytotoxicity and serves as a powerful tool to investigate a variety of therapeutic modalities, monotherapy or in combination, to identify patient-specific treatment strategies.